• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

作者信息

Schmid Sabine, Früh Martin, Peters Solange

机构信息

Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology Lung Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.

Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland; Department of Medical Oncology, University of Berne, Berne, Switzerland.

出版信息

Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3.

DOI:10.1016/S1470-2045(19)30859-9
PMID:32027845
Abstract
摘要

相似文献

1
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?在非小细胞肺癌的表皮生长因子受体（EGFR）耐药中靶向间质上皮转化因子（MET）——是否适用于日常实践？
Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3.
2
Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.非小细胞肺癌对奥希替尼加 savolitinib 有反应。
Cancer Discov. 2020 Apr;10(4):487. doi: 10.1158/2159-8290.CD-RW2020-025. Epub 2020 Feb 14.
3
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.奥希替尼联合 savolitinib 治疗 EGFR 突变阳性、MET 扩增的非小细胞肺癌患者：EGFR 酪氨酸激酶抑制剂进展后的多中心、开放标签、Ib 期研究的中期结果。
Lancet Oncol. 2020 Mar;21(3):373-386. doi: 10.1016/S1470-2045(19)30785-5. Epub 2020 Feb 3.
4
Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.克服非小细胞肺癌对奥希替尼的耐药性：希望、疑虑与中间地带。
Cancer. 2020 Jun 1;126(11):2594-2596. doi: 10.1002/cncr.32810. Epub 2020 Mar 10.
5
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.表皮生长因子受体（EGFR）C797S突变介导T790M阳性非小细胞肺癌对第三代抑制剂的耐药性。
J Hematol Oncol. 2016 Jul 22;9(1):59. doi: 10.1186/s13045-016-0290-1.
6
Osimertinib in EGFR Mutation-Positive Advanced NSCLC.奥希替尼用于表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌
N Engl J Med. 2018 Mar 29;378(13):1262-1263. doi: 10.1056/NEJMc1801669.
7
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.塔顿：奥希替尼联合塞来替尼、索凡替尼或度伐鲁单抗治疗 EGFR 突变型肺癌的多臂 Ib 期试验。
Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24.
8
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?奥希替尼用于中枢神经系统进展的表皮生长因子受体（EGFR）突变型肺癌：我们是否需要检测T790M？
Ann Oncol. 2020 Nov;31(11):1581-1582. doi: 10.1016/j.annonc.2020.07.021. Epub 2020 Aug 13.
9
Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With After Osimertinib First-Line Treatment.在奥希替尼一线治疗后，横纹肌肉瘤样转化作为表皮生长因子受体（EGFR）突变型肺腺癌对奥希替尼和萨伏替尼耐药的一种机制。
JCO Precis Oncol. 2022 Oct;6:e2200367. doi: 10.1200/PO.22.00367.
10
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.罕见的表皮生长因子受体（EGFR）G724S突变出现在对第一代EGFR酪氨酸激酶抑制剂产生获得性耐药的非小细胞肺癌患者中。
Lung Cancer. 2018 Apr;118:173-175. doi: 10.1016/j.lungcan.2018.02.016. Epub 2018 Mar 2.

引用本文的文献

1
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation.MET和VEGF的联合抑制增强了EGFR酪氨酸激酶抑制剂对伴有MET异常激活的EGFR突变非小细胞肺癌的治疗效果。
Exp Hematol Oncol. 2024 Oct 1;13(1):97. doi: 10.1186/s40164-024-00565-9.
2
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.用于治疗肺癌的药物偶联物：从药物发现到临床实践
Exp Hematol Oncol. 2024 Mar 1;13(1):26. doi: 10.1186/s40164-024-00493-8.
3
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations.
新一代酪氨酸激酶抑制剂治疗具有癌基因成瘾性的非小细胞肺癌：优势与局限
Cancers (Basel). 2023 Oct 20;15(20):5079. doi: 10.3390/cancers15205079.
4
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.109695 例实体瘤组织基础综合基因组图谱的临床意义分析。
Oncologist. 2024 Feb 2;29(2):e224-e236. doi: 10.1093/oncolo/oyad251.
5
SETD8 inhibits ferroptosis in pancreatic cancer by inhibiting the expression of RRAD.SETD8通过抑制RRAD的表达来抑制胰腺癌中的铁死亡。
Cancer Cell Int. 2023 Mar 18;23(1):50. doi: 10.1186/s12935-023-02899-6.
6
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.非小细胞肺癌中的分子通路、耐药机制及靶向干预
Mol Biomed. 2022 Dec 12;3(1):42. doi: 10.1186/s43556-022-00107-x.
7
An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）与联合治疗用于晚期EGFR突变阳性非小细胞肺癌一线治疗的最新网状Meta分析
Front Oncol. 2022 Aug 1;12:616546. doi: 10.3389/fonc.2022.616546. eCollection 2022.
8
Non-small-cell lung cancer: how to manage -mutated disease.非小细胞肺癌：如何应对 - 突变疾病。
Drugs Context. 2022 Aug 3;11. doi: 10.7573/dic.2022-4-1. eCollection 2022.
9
Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.通过适配体修饰的纳米粒子靶向共递 gefitinib 和 rapamycin 可通过促进自噬克服 NSCLC 中的 EGFR-TKI 耐药性。
Int J Mol Sci. 2022 Jul 21;23(14):8025. doi: 10.3390/ijms23148025.
10
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.寡转移和寡进展性非小细胞肺癌肿瘤微环境的叙述性综述：仍有许多工作要做。
Transl Lung Cancer Res. 2021 Jul;10(7):3369-3384. doi: 10.21037/tlcr-20-1134.